Drug Profile
TS 01
Alternative Names: TS01Latest Information Update: 22 Sep 2023
Price :
$50
*
At a glance
- Originator Beth Israel Deaconess Medical Center; Harvard Medical School
- Developer Thrombolytic Science International
- Class Complement C1 inactivator proteins; Neuroprotectants; Recombinant proteins; Thrombolytics; Vascular disorder therapies
- Mechanism of Action Fibrinolytic agents; Urokinase-type plasminogen activator stimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase II Stroke
Most Recent Events
- 26 May 2022 Thrombolytic Science in collaboration with Erasmus Medical Center completes a phase II DUMAS trial in Stroke in Netherlands (IV, Infusion) (NCT04256473)
- 10 Jan 2022 US PTO grants patent protection for TS 01 for treatment of Stroke
- 29 Oct 2021 Thrombolytic Science has patent protection for TS 01 in USA, Europe, Japan, China, Hong Kong, Mexico and Commonwealth of Independent States